Ibrutinib: Brands, Price & Uses in Bangladesh

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of several B-cell lymphoid malignancies and chronic graft-versus-host disease (cGVHD).

Established / FDA-approved indications

• Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), including patients with 17p deletion — as first-line therapy or in relapsed/refractory disease, given alone or in combination with an anti-CD20 antibody such as rituximab or obinutuzumab.
• Waldenström's macroglobulinemia (WM) — as monotherapy or in combination with rituximab.
• Chronic graft-versus-host disease (cGVHD) in adult and pediatric patients (1 year of age and older) after failure of one or more prior lines of systemic therapy.

Historically approved / off-label use (evidence-limited)

• Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy — this indication received earlier accelerated approval but was later voluntarily withdrawn after confirmatory trials failed to show a survival benefit and raised safety concerns; Ibrutinib may still be used off-label in select relapsed/refractory MCL cases at physician discretion when other options are limited.
• Marginal zone lymphoma (MZL) requiring prior anti-CD20-based therapy — similarly an earlier accelerated approval that was voluntarily withdrawn; use is now considered off-label.

The decision to use Ibrutinib for any indication, and the specific regimen (monotherapy versus combination), should be individualized by a hematologist/oncologist based on disease characteristics, prior therapy, and patient fitness.

General instructions

• Ibrutinib capsules/tablets should be swallowed whole with a glass of water, at approximately the same time each day. Do not open, break, or chew capsules.
• Take consistently either with or without food, but be consistent with the chosen approach.
• Avoid grapefruit, grapefruit-containing products, and Seville oranges during treatment, as they raise Ibrutinib blood levels (see Interactions).
• If a dose is missed, it may be taken as soon as possible on the same day, with a return to the normal schedule the next day; do not take two doses together to make up for a missed dose.

Dosing by indication

Dose modification for drug interactions

Dose must be reduced when Ibrutinib is co-administered with moderate or strong CYP3A4 inhibitors, and such combinations (especially strong inhibitors) should generally be avoided; see Interactions for details.

Hepatic impairment

• Mild impairment (Child-Pugh A): reduced starting dose recommended.
• Moderate impairment (Child-Pugh B): further reduced starting dose recommended, with close monitoring for toxicity.
• Severe impairment (Child-Pugh C): Ibrutinib is generally not recommended unless the anticipated benefit clearly outweighs the risk, given limited safety data.

Renal impairment

Only a small fraction of Ibrutinib is renally eliminated. No dose adjustment is generally required for mild-to-moderate renal impairment. Data are limited in severe renal impairment (creatinine clearance <30 mL/min) or dialysis-dependent patients; use with caution and monitor closely in these patients.

The most common adverse effects of Ibrutinib, several of which relate to its serious safety risks discussed under Precautions and Warnings, include:

• Diarrhea, nausea, constipation, mouth sores (stomatitis)
• Fatigue, musculoskeletal pain, arthralgia
• Bruising (contusion) and other minor bleeding/rash
• Low blood counts: thrombocytopenia, neutropenia, anemia
• Upper respiratory tract infections, fever
• Peripheral edema
• Hypertension

Less common but serious effects — major hemorrhage, severe infections, cardiac arrhythmias (including atrial fibrillation/flutter), secondary cancers, and tumor lysis syndrome — are covered under Precautions and Warnings, as these require specific monitoring and clinical action rather than routine tolerance.